Moreau P, Dimopoulos MA, Mikhael J, et al. - Researchers compared isatuximab plus carfilzomib–dexamethasone vs carfilzomib–dexamethasone, in terms of efficacy in treating patients with relapsed multiple myeloma in this phase 3, open-label study. Eligible patients were those with relapsed or refractory multiple myeloma aged at least 18 years who had undergone one to three previous lines of therapy and had measurable serum or urine M-protein. Patients were randomized (3:2) to isatuximab plus carfilzomib–dexamethasone (isatuximab group) or carfilzomib–dexamethasone (control group). Findings revealed that significant improvements in progression-free survival as well as depth of response were conferred by the addition of isatuximab to carfilzomib–dexamethasone for treating patients with relapsed multiple myeloma, thus, it affords a new standard of care for this patient population.